Cefmenoxime (Cefmax)

A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.

Also Known As:

Networked: 122 relevant articles (14 outcomes, 20 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Ohashi, Yuichi: 1 article (07/2013)
2.	Suzuki, Takashi: 1 article (07/2013)
3.	Toshida, Hiroshi: 1 article (01/2012)
4.	Ishizuka, Tetsuya: 1 article (01/2012)
5.	Suto, Chikako: 1 article (01/2012)
6.	Kamiya, Kazutaka: 1 article (01/2009)
7.	Kasahara, Masayuki: 1 article (01/2009)
8.	Shimizu, Kimiya: 1 article (01/2009)
9.	Matsuzaki, Kaoru: 1 article (02/2005)
10.	Sato, Yumie: 1 article (02/2005)

Related Diseases

1.	Infection 03/01/1983 - "In the cefmenoxime group, all except one urethral infection were eradicated. " 01/01/1985 - "On the whole, this study showed a significant placental transfer of cefmenoxime, achieving therapeutic concentrations required against microorganisms responsible for obstetrical infections." 05/01/1984 - "On the whole, this study showed a significant placental transfer of cefmenoxime, achieving therapeutic concentrations required against microorganisms responsible for obstetrical infections." 10/01/1982 - "[Laboratory and clinical studies of cefmenoxime in pediatric infections]." 06/01/1982 - "The study group was organized to evaluate the usefulness of cefmenoxime (CMX) injection, a new synthetic cephalosporin, for the treatment of infections in the field of obstetrics and gynecology. "
2.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/1990 - "Schentag et al studied patients with lower respiratory tract infection treated with cefmenoxime alone and found a significant relationship between time greater than MIC & time to clearance of the pathogen from cultures of the tracheobronchial tree. " 09/01/1988 - "[Study on the effectiveness and safety of cefmenoxime in the treatment of respiratory tract infections. " 11/01/1986 - "[Laboratory and clinical studies on cefmenoxime in respiratory tract infections]." 01/01/1983 - "This bacteriological and pharmacokinetic study was therefore performed in order to evaluate the potency of cefmenoxime in the treatment of respiratory infections. " 09/01/1988 - "The effectiveness and safety of cefmenoxime (CMX) in the treatment of respiratory tract infections were evaluated, mainly in relation to the appearance of hemorrhagic tendency. "
3.	Urinary Tract Infections (Urinary Tract Infection) 06/01/1985 - "Cefmenoxime (CMX) was intravenously administered to 106 patients with complicated urinary tract infection at a daily dose of 2-4 g for 5 days. " 06/01/1985 - "[Clinical experience with cefmenoxime (CMX) in complicated urinary tract infections]." 02/01/1985 - "Cefmenoxime (CMX), a new semisynthetic antibiotic, was administrated in 29 cases diagnosed as complicated urinary tract infection. " 02/01/1985 - "[Clinical evaluation of cefmenoxime (CMX) for complicated urinary tract infection]." 01/01/1985 - "[Clinical evaluation of cefmenoxime in chronic complicated urinary tract infection]."
4.	Meningitis 02/01/1986 - "Efficacy of cefmenoxime in experimental group B streptococcal bacteraemia and meningitis." 05/01/1985 - "[Cefmenoxime diffusion into cerebrospinal fluid during human purulent meningitis]." 09/01/1985 - "Efficacy of cefmenoxime in experimental Escherichia coli bacteremia and meningitis." 02/01/1986 - "In-vivo studies using experimental bacteraemia and meningitis in newborn rats revealed that despite similar drug levels, cefmenoxime had significantly greater bactericidal titres in blood at 6-7 h after administration and bacterial clearance from blood was significantly faster with cefmenoxime than with penicillin G at the end of one day of treatment. " 01/01/1985 - "Two grams of cefmenoxime (CMX) was administered by one-shot intravenous injection to the patients in normal pressure hydrocephalus without meningitis, and the transference of CMX into the cerebrospinal fluid (CSF) from blood was investigated. "
5.	Sepsis (Septicemia) 01/01/1993 - "The elimination of cefmenoxime after single and repeated i.v. dosing was studied in 12 patients with severe renal failure and sepsis during continuous haemofiltration. " 07/01/1984 - "Cefmenoxime, a new semisynthetic third-generation cephalosporin, was evaluated in 105 patients (45 men and 60 women) with the following infections: skin or skin structure (33), pulmonary (22), urinary tract (30), and septicemia (20). " 12/01/1989 - "1. Cefmenoxime (CMX) was administered with a dosage regimen of 20-25 mg/kg, 2-3 times daily (40-75 mg/kg/day) by intravenous drip over 30 minutes to 9 neonates with bacterial infections including purulent meningitis and septicemia. " 12/01/1980 - "Its therapeutic efficacy against experimental septicemias in mice was equal to or slightly superior to that of cefotaxime and SCE-1365 when the antibiotics were administered in repeated subcutaneous doses after bacterial challenge. " 06/01/1984 - "[Bacteriologic, clinical and kinetic evaluation of cefmenoxime (SCE 1365) in the treatment of 68 cases of septicemia. "

Related Drugs and Biologics

1.	Cefotiam
2.	Cefotaxime (Kendrick)
3.	Cefsulodin
4.	Penicillins (Penicillin)
5.	Penicillin G (Benzylpenicillin)
6.	Amikacin (A.M.K)
7.	beta-Lactamases (beta-Lactamase)
8.	Anti-Bacterial Agents (Antibiotics)
9.	Cefazolin (Ancef)
10.	Cephalosporins (Cephalosporin Antibiotics)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Gynecologic Surgical Procedures (Gynecologic Surgery)
3.	Intravenous Infusions
4.	Critical Care
5.	Intravenous Injections